本页面由Tiger Trade Technology Pte. Ltd.提供服务

诺瓦瓦克斯医药

8.69
+0.30003.58%
盘前8.720.0300+0.35%07:39 EDT
成交量:296.23万
成交额:2,559.85万
市值:14.12亿
市盈率:3.37
高:8.79
开:8.38
低:8.38
收:8.39
52周最高:11.97
52周最低:5.80
股本:1.62亿
流通股本:1.37亿
量比:0.95
换手率:2.17%
股息:- -
股息率:- -
每股收益(TTM):2.58
每股收益(LYR):2.58
净资产收益率:-898.20%
总资产收益率:25.72%
市净率:-11.05
市盈率(LYR):3.37

数据加载中...

2024/11/12

重要事件披露

Form 8-K - Current report
2024/11/05

重要事件披露

Form 8-K - Current report
2024/10/16

重要事件披露

Form 8-K - Current report
2024/10/03

重要事件披露

Form 8-K - Current report
2024/09/18

关联方拟减持公告

Form 144 | NOVAVAX高管Filip Dubovsky拟减持7335股,总价约95331美元
2024/08/09

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/08/08

重要事件披露

Form 8-K - Current report
2024/08/08

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/06/20

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/06/18

关联方拟减持公告

Form144|诺瓦瓦克斯公司董事James F.Young拟减持15000股,总价约20.57万美元
2024/06/17

关联方拟减持公告

Form144|诺瓦瓦克斯高管Filip Dubovsky拟减持13904股,总价约20万美元
2024/06/14

重要事件披露

Form 8-K - Current report
2024/06/06

重要事件披露

Form 8-K - Current report
2024/05/23

重要事件披露

Form 8-K - Current report
2024/05/20

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/05/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/05/13

重要事件披露

Form 8-K - Current report
2024/05/10

重要事件披露

Form 8-K - Current report
2024/05/10

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/05/07

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]